Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fate Therapeutics Inc. (FATE:NASDAQ), powered by AI.
Fate Therapeutics Inc. is currently trading at $1.37. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fate Therapeutics Inc. on Alpha Lenz.
Fate Therapeutics Inc.'s P/E ratio is -0.8.
“Fate Therapeutics Inc. trades at a P/E of -0.8 (undervalued) with modest ROE of -54.2%.”
Ask for details →Fate Therapeutics Inc. operates within the biotechnology sector, specializing in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's key focus lies in creating off-the-shelf cellular therapy candidates by using pluripotent stem cells combined with proprietary cell programming technology. This unique approach aims to generate a consistent and scalable source of cell-based therapies. Fate Therapeutics is at the forefront of innovation within its field, working on therapies that possess the potential to transform current treatment paradigms in oncology and immunology. As a significant player in the biotech arena, Fate collaborates with other industry leaders and research institutions to advance its product pipeline. Established in the early 2000s and headquartered in San Diego, California, the company is strategically positioned to address critical unmet medical needs, potentially impacting patients worldwide by offering novel therapeutic solutions in challenging medical domains. Its efforts underline the growing importance and potential of cellular therapies in modern medicine.
“Fate Therapeutics Inc. trades at a P/E of -0.8 (undervalued) with modest ROE of -54.2%.”
Ask for details →Fate Therapeutics Inc. (ticker: FATE) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 181 employees. Market cap is $156M.
The current price is $1.37 with a P/E ratio of -0.84x and P/B of 0.49x.
ROE is -54.21% and operating margin is -1434.52%. Annual revenue is $14M.